[Urinary tumor marker for urothelial cancer].
The urinary tumor markers BTA, BFP and NMP22 used for urothelial cancer in Japan are reviewed briefly. We also evaluate and compare the sensitivity and specificity of BTA, BFP and NMP22 with urine cytology in detecting bladder cancer in 24 of our patients. The results showed that the sensitivity with urine cytology, BTA, BFP and NMP22 was 37, 54, 66 and 62% respectively. The specificity of BTA, BFP and NMP22 with urine cytology was 100, 65, 60 and 70% respectively. The sensitivity with BTA, BFP and NMP22 for urothelial cancer was higher than that with urine cytology. However, all except for urine cytology showed high false positive rates (83-90%) for urinary tract infection. These markers may thus complement urine cytology, which has a low sensitivity for urothelial cancer. Quite possibly they could act as low-cost and useful tumor markers, which could in turn reduce the number of invasive cystoscopic examinations. However, considering their high false positive rates for benign disease such as urinary tract infection, we must acknowledge that an ideal urothelial tumor marker, which is simple, non-invasive, inexpensive and accurate with high sensitivity and specificity has yet to be developed.
Ohtani
M
M
Dept. of Urology, Ibaraki Prefectural Central Hospital and Cancer Center, 6528 Koibuchi, Tomobe-machi, Nishiibaraki-gun, Ibaraki 309-1793, Japan.
Iwasaki
A
A
Shiraiwa
H
H
D000951:Antigens, Neoplasm / Q000652:urine; D014408:Biomarkers, Tumor / Q000652:urine*; D006801:Humans; D009687:Nuclear Proteins / Q000652:urine; D019098:Telomerase / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine; D014556:Urine / Q000166:cytology; D014571:Urologic Neoplasms / Q000175:diagnosis* / Q000652:urine; D000509:alpha-Fetoproteins / Q000652:urine
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; D000509:alpha-Fetoproteins; C112999:bladder tumor-associated antigen; C100379:nuclear matrix protein 22; D019098:Telomerase